摘要
To date,five coronavirus disease 2019(COVID-19)vaccines have been conditionally approved for market authorization or granted emergency use authorization in China by the National Medical Products Administration(NMPA).Three inactivated COVID-19 vaccines and one adenovirus-vectored vaccine were granted conditional approval,as phaseⅢclinical trial data for these four conditionally-approved vaccines have demonstrated protective efficacy levels that meet requirements of NMPA’s Guidelines for Clinical Evaluation of COVID-19 vaccine(interim version)and also meet requirements recommended by the World Health Organization(WHO)in their COVID-19 Vaccines Target Product Profile.
